Mayo Clinic today recognized a multi-cancer early cancer detection (MCED) test called Galleri that can detect more than 50 types of cancers through a simple blood draw.
the Circulating Cell-free Genome Atlas (CCGA) Study - a prospective, observational, longitudinal study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer.
Dr. Liu is the co-director of the Genomics in Action Program within the Mayo Clinic Center for Individualized Medicine, research chair of the Department of Oncology, and a consultant in the Department of Laboratory Medicine and Pathology.
The test uses cell-free deoxyribonucleic acid (cfDNA) targeted methylation signals in the blood to provide a cancer signal and information about the tissue of origin.